Altamira Therapeutics (CYTO): Company Cash Volume

Altamira Therapeutics - graphic logo of issuer CYTO

Altamira Therapeutics (CYTO) attracts molecular biologists with high salaries and a Swiss approach to the development of RNA sprays. The size of the cash balance helps assess the dynamics of liquid reserves, with the value fixed at 0.00. Development relies on an ecosystem of intranasal drugs dependent on regulatory verdicts and the hiring of experts in drug delivery to brain and ear tissues.

Company Cash Balance: Altamira Therapeutics (CYTO) for 07/04/2022 - 01/04/2025

Financial and market metric breakdowns for Altamira Therapeutics Ltd. (CYTO)

- stock value and consensus price forecast:
Summary company analysis:Altamira Therapeutics
Product sample of altamiratherapeutics.com

This indicator reflects the level of immediate liquidity, allowing for an assessment of the issuer's ability to cover operating expenses without raising external capital. The algorithm eliminates time gaps between reports, converting static data into a continuous flow. By analyzing the current cash balance, an investor determines the company's financial cushion. For Altamira Therapeutics (CYTO), such reserves are critical when hiring rare, highly specialized scientists. A stable balance of funds ensures the development of innovative drug delivery methods to the brain and ear.

Direct competitors

Company Cash Funds Haleon (HLN)|Company Cash Volume Kenvue Inc. (KVUE)|Company Cash Volume VRNA (veronapharma.com)|Company Cash Balance MENS|LGND: Company Cash on Hand|Company Cash Balance AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Company Cash on Hand|Alvotech - Company Cash Balance|Company Cash on Hand LQDA|Galapagos Genomics (GLPG) - Company Liquid Assets|Company Cash Volume ANIP|Company Cash on Hand Afrezza MNKD|Company Cash Funds Amphastar AMPH|Company Liquid Assets Pacira BioSciences (PCRX)|ARS Corp - Company Cash Volume|TBPH: Company Cash Funds|AQST: Company Cash Volume|SCPH - Company Liquid Assets|TECX (Tectonic) - Company Cash Volume|Company Cash Reserve Tonix Pharmaceuticals Holding Corp. TNXP|Company Cash Funds SXT Pharmaceuticals (SXTC)|Company Cash Volume Eupraxia Pharmaceuticals Inc. (EPRX)|Company Cash Funds BioHarvest Sciences BHST|EXOZ (Invizyne) - Company Total Cash Volume|ORMP: Company Cash on Hand|ENTX (Entera Bio Ltd) - Company Cash and Cash Equivalents|HYFT: Company Cash Volume|Company Cash on Hand ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Company Cash Volume|Company Cash Funds QNTM|Company Cash Volume FGEN|Company Cash on Hand Telomir Pharmaceuticals TELO|Company Cash Volume RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Company Total Cash Volume|RLYB - Company Cash Funds|LEXX (Lexaria Bioscience Corp.) - Company Cash and Cash Equivalents|pulmatrix.com (PULM) - Company Cash Funds|PTHL (Pheton) - Company Cash Funds|Company Cash Funds Aptorum|Company Cash Reserve Lyra Therapeutics Inc. LYRA|Company Cash Volume IBO|TNFA (TNF Pharmaceuticals, Inc.) - Company Cash Balance|Company Cash Funds cbdMD, Inc. YCBD|Company Cash Balance PRFX|LIPO - Company Cash Funds|Company Cash Balance OPTN (OptiNose)|PIRS: Company Cash Volume|Procaps Group S.A. (PROC) - Company Cash Volume|PTPI (Petros Pharma) - Company Cash Volume|QLI: Company Cash Balance|Company Cash Volume SLRN|TFFP (TFF Pharmaceuticals Inc.) - Company Cash Balance